… -mutant cancers. In vitro studies demonstrated a tendency toward sensitivity to MEK inhibitors
in cell lines harboring KRAS mutations compared with those without KRAS mutations (18, …

… of KRAS mutant cancer cells to MEK inhibitor varied extensively despite efficient MEK pathway
inhibition in … We noted that the majority of MEK inhibitor–insensitive cell lines harbored …

… To gather insights into genes capable of complementing MEK inhibition in KRAS mutant cells
insensitive … We propose that, in a KRAS mutant background, MEK inhibition triggers KRAS …

… known as cobimetinib), a MEK inhibitor currently in phase III clinical trials. … MEK in KRAS-mutant
tumours versus BRAF-mutant tumours can be exploited through the design of inhibitors …

… MEK inhibitors in KRAS mutant tumors vary, owing to specific properties of drug-bound MEK…
We hypothesized that the ability of MEK inhibitors to inhibit the proliferation of KRAS mutant …

… state of MEK and ERK inhibitors in pre-clinical models and in human clinical trials for … MEK
inhibitor to date [75], single agent MEK inhibitors have only marginal activity in KRAS mutant …

… To investigate the mechanism of this response to MEK inhibition, we first explored
whether PD0325901 treatment eliminated Kras mutant cells from the bone marrow. We used …

… wild-type KRAS-dependent fitness of human and murine KRAS mutant LUAD … MEK inhibition.
These effects are abrogated when wild-type KRAS is replaced by KRAS D154Q , a mutant …

… /MEK inhibitors in the treatment of this disease. We describe the recent development of
the selective MEK inhibitor … with AKT inhibitor MK-2206 in KRAS mutant cancers, Citation101 …

… mutations of genes in addition to KRAS mutations impact the activity of MEK inhibitors, or
specific subsets of KRAS mutations may be resistant or susceptible to MEK inhibition. Other …